John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$510M |
| 2 |
Broadcom
AVGO
|
+$318M |
| 3 |
Marvell Technology
MRVL
|
+$290M |
| 4 |
Salesforce
CRM
|
+$263M |
| 5 |
Advanced Micro Devices
AMD
|
+$250M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$255M |
| 2 |
Progressive
PGR
|
+$244M |
| 3 |
Visa
V
|
+$238M |
| 4 |
Lam Research
LRCX
|
+$201M |
| 5 |
Elevance Health
ELV
|
+$190M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.88% |
| 2 | Healthcare | 13.28% |
| 3 | Financials | 10.32% |
| 4 | Industrials | 9.79% |
| 5 | Consumer Discretionary | 8.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2976
Real Brokerage
REAX
$523M
| $51.5K | ﹤0.01% |
12,696
-27,930
| -69% | -$133K |
|
|
UNIT
2977
PUT
Uniti Group
UNIT
$2.39B
| $50.4K | ﹤0.01% |
10,000
| – | – |
|
|
ELEV
2978
DELISTED
Elevation Oncology
ELEV
| $50.3K | ﹤0.01% |
194,016
-21,934
| -10% | -$12.5K |
|
2979
CEL-SCI Corp
CVM
$24.3M
| $50.1K | ﹤0.01% |
7,247
+4,527
| +166% | +$49K |
|
2980
GrafTech
EAF
$169M
| $48.7K | ﹤0.01% |
5,567
+4,534
| +439% | +$58.9K |
|
2981
Air Industries Group
AIRI
$11.3M
| $48.3K | ﹤0.01% |
13,878
-4,382
| -24% | -$17.9K |
|
2982
BRC Inc
BRCC
$133M
| $48.3K | ﹤0.01% |
2,309
-3,757
| -62% | -$95.7K |
|
2983
GEE Group
JOB
$28M
| $47.5K | ﹤0.01% |
+235,085
| New | +$53.9K |
|
|
KRON
2984
DELISTED
Kronos Bio
KRON
| $46.1K | ﹤0.01% |
55,935
-7,326
| -12% | -$7.06K |
|
2985
Relmada Therapeutics
RLMD
$489M
| $46K | ﹤0.01% |
170,544
+42,965
| +34% | +$14.2K |
|
|
INTZ
2986
Intrusion
INTZ
$15.3M
| $44.8K | ﹤0.01% |
+39,999
| New | +$66.2K |
|
2987
Navitas Semiconductor
NVTS
$3.19B
| $44.8K | ﹤0.01% |
+21,850
| New | +$62.6K |
|
|
MGRM
2988
DELISTED
Monogram Orthopaedics
MGRM
| $44.8K | ﹤0.01% |
+15,235
| New | +$40.3K |
|
|
NNDM
2989
Nano Dimension
NNDM
$325M
| $44K | ﹤0.01% |
27,642
-83,154
| -75% | -$188K |
|
2990
Rallybio
RLYB
$89.2M
| $43.7K | ﹤0.01% |
8,339
-1,262
| -13% | -$7.97K |
|
2991
Maris-Tech
MTEK
$11.7M
| $43.5K | ﹤0.01% |
+20,235
| New | +$60.1K |
|
2992
Rafael Holdings
RFL
$114M
| $43.2K | ﹤0.01% |
23,436
-783
| -3% | -$1.52K |
|
2993
Caesarstone
CSTE
$118M
| $43.1K | ﹤0.01% |
17,717
-5,162
| -23% | -$19.3K |
|
|
GBIO
2994
DELISTED
Generation Bio
GBIO
| $42.7K | ﹤0.01% |
10,555
-1,485
| -12% | -$10.4K |
|
2995
Bridger Aerospace
BAER
$68.8M
| $42.5K | ﹤0.01% |
+37,592
| New | +$82.6K |
|
2996
FTC Solar
FTCI
$35.2M
| $41K | ﹤0.01% |
+14,285
| New | +$50.3K |
|
2997
Century Therapeutics
IPSC
$384M
| $40.9K | ﹤0.01% |
86,006
+19,209
| +29% | +$14.4K |
|
2998
Goldgroup Mining
GORO
$266M
| $40.5K | ﹤0.01% |
79,510
-12,286
| -13% | -$5.09K |
|
2999
XBiotech
XBIT
$70.4M
| $40.2K | ﹤0.01% |
+12,393
| New | +$42.7K |
|
3000
KULR Technology Group
KULR
$119M
| $39.7K | ﹤0.01% |
3,758
+1,233
| +49% | +$19.3K |
|
Similar funds
John Overdeck's Q1 2025 Portfolio in Review
As of Q1 2025, John Overdeck held 3,617 positions worth $46.8B, up 2% from $45.9B the previous quarter. Its ten largest holdings account for 8.1% of the portfolio.
John Overdeck deployed $2.08B of net new capital in Q1 2025, opening 458 new positions and adding to 1,225 existing holdings. Its largest new stake was Advanced Micro Devices: 2,246,952 shares worth $231M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 16% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Eli Lilly, an estimated $255M trimmed.
- John Overdeck's largest Q1 2025 buy was Advanced Micro Devices: 2,246,952 shares worth $231M.
- John Overdeck added most to State Street SPDR S&P 500 ETF Trust in Q1 2025, an estimated $510M increase.
- John Overdeck's biggest Q1 2025 reduction was Eli Lilly, cutting an estimated $255M.
- John Overdeck fully exited Coinbase in Q1 2025, selling an estimated $45M.
- John Overdeck's ten largest holdings make up 8.1% of its $46.8B portfolio in Q1 2025.
- John Overdeck opened 458 new positions and closed 452 in Q1 2025.
- John Overdeck's portfolio value rose 2% quarter-over-quarter to $46.8B.
Based on Two Sigma Investments's 13F filing for Q1 2025, filed 15 May 2025.